Navigation Links
Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Date:11/16/2010

REG2 and REG3  Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, presently in a phase 2b clinical trial (the RADAR trial), is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients intended for Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERSPegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
2. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
3. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
4. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
5. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
6. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
7. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
10. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
11. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Heart ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html About Heart ... in the human heart which control the flow ... affected with heart valve diseases such as valvular ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new market ... Baby Food Eastern Europe 2014 ... 2014" is a new report by ERC that analyzes ... Eastern Europe , key segments, features & developments, ... examines trends which are currently affecting the industry. Furthermore, ...
(Date:8/27/2014)... North American lighting leader OSRAM SYLVANIA ... the new OSRAM ITOS ® PHASER ® 3000, ... microscopy, endoscopy and surgical head lamps that delivers the same ... lamp life. "We,re honored to be recognized by ... new technologies of the past year," said Andreas Osten ...
Breaking Medicine Technology:Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3
(Date:8/27/2014)... Spring, Md. (PRWEB) August 27, 2014 ... (CHEST) recently released guidelines for the management and ... Pharmacological Therapy for Pulmonary Arterial Hypertension in Adults: ... are free to view for clinicians, and provide ... PAH. , The Pulmonary Hypertension Association ...
(Date:8/27/2014)... Seventy-three members of the founding class of the ... their careers as healthcare professionals at a traditional White ... four-year PharmD program traditionally receive white coats?a symbol of ... profession as colleagues dedicated to patient care. At the ... in Claremont, Calif., KGI President Sheldon Schuster welcomed the ...
(Date:8/27/2014)... Aug. 27, 2014 (HealthDay News) -- Young adults who ... networks in their brain, researchers are reporting. The ... to new ways to predict, prevent and treat the ... researchers. The researchers conducted brain scans on 30 ... their teen years, and a control group of 23 ...
(Date:8/27/2014)... Texas (PRWEB) August 28, 2014 BRIC ... Outlook to 2020?, provides key market data on the ... of US dollars, volume (in units) and average prices ... Tip Video Laparoscopes and Flexible Tip Video Laparoscopes), Robotic ... are a number of advantages to the patient with ...
(Date:8/27/2014)... 27, 2014 Sound Telecom, a leading ... and cloud-based business communication systems, has unveiled an article ... HIPAA-compliant Secure Text Messaging .” The piece examines the ... to do to remain compliant with HIPAA and HITECH ... article and C.O.O. at Sound Telecom, opens with evidence ...
Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2Health News:Founding Class of the KGI School of Pharmacy Formally Welcomed into the Profession at a Traditional White Coat Ceremony 2Health News:Study: Young Adults Who Had Depression Have 'Hyper-Connected' Brain Networks 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 4Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 2Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 3
... Using the same technology found in clothing tags used in ... North Carolina at Chapel Hill shows that surgical sponges with ... to manual counting and X-ray detection in preventing sponges from ... UNC surgeons will report the preliminary results of the study ...
... new form of immunotherapy to children with neuroblastoma, a ... were alive and free of disease progression after two ... San Diego School of Medicine and fellow institutions. The ... standard therapy to 66 percent for children receiving immunotherapy ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Sept. ... a progestin hormone may be an effective treatment for ... By delaying a total hysterectomy, which is the ... to remain fertile and possibly to have families, according ...
... program headed by Washington University School of Medicine ... for heart and lung diseases that use,nanotechnology. ... Blood Institute, will fund five years of research ... University, University of Texas Southwestern Medical Center, and ...
... MD, an assistant professor in the department of medicine ... the Department of Defense Lung Cancer Promising Clinician Research ... factors in the progression of lung cancer. It is ... the molecular progression of lung tumors and help identify ...
... HealthDay Reporter , TUESDAY, Sept. 28 (HealthDay News) ... specific proteins may indicate the presence of prostate cancer more ... The test, which has thus far only been ... returned fewer false-positive results than the prostate specific antigen (PSA) ...
Cached Medicine News:Health News:No sponge left behind 2Health News:Addition of immunotherapy boosts pediatric cancer survival in children with neuroblastoma 2Health News: IUD Proposed to Treat Uterine Cancer 2Health News: IUD Proposed to Treat Uterine Cancer 3Health News:WUSTL awarded $18 million to treat heart, lungs with nanotechnology 2Health News:WUSTL awarded $18 million to treat heart, lungs with nanotechnology 3Health News:BU School of Medicine researcher receives Department of Defense award 2Health News:Experimental Test May Spot Prostate Cancer Earlier, More Accurately 2Health News:Experimental Test May Spot Prostate Cancer Earlier, More Accurately 3
... super series slit ... Examination through small ... fundus diagnostic capability, ... potential field of ...
... Volk's super ... biomicroscopy lenses. General ... Provide unprecedented fundus ... addressing maximum potential ...
Volk indirect lenses. General diagnosis / small pupil examinations....
Volk indirect lenses. General diagnosis & treatment....
Medicine Products: